#POLB Poolbeg Pharma PLC – Termination of proposed combination with HOOKIPA February 21, 2025 – Posted in: Poolbeg Pharma (POLB) – Tags: discussions, opportunities, programmes, shareholders, termination
Further to the 2.4 announcement on 2 January 2025 on the potential combination of Poolbeg Pharma (“Poolbeg” or the “Company”) and HOOKIPA Pharma Inc (“HOOKIPA”), the Board of Poolbeg announces that it was informed yesterday that HOOKIPA has terminated discussions on the proposed combination of the two companies.
Cathal Friel, Executive Chairman of Poolbeg, said: “We were surprised and disappointed to hear of HOOKIPA’s decision to withdraw from the combination discussions. Throughout this process, we have seen strong interest in the potential of POLB 001 and we continue to be focused on maximising the potential of our in-house programmes and exploring new opportunities to generate value for our shareholders.”
ENDS
|
Enquiries:
|
|
|
Poolbeg Pharma Plc |
+44 (0) 207 183 1499 |
|
Cathal Friel, Chairman |
ir@Poolbegpharma.com |
|
Jeremy Skillington, CEO |
|
|
Ian O’Connell, CFO
|
|
|
|
|
|
Cavendish Capital Markets Ltd (Joint Financial Adviser and Rule 3 Adviser to Poolbeg, NOMAD & Joint Broker) |
+44 (0) 207 220 0500 |
|
Corporate Finance Geoff Nash Henrik Persson Hamish Waller Trisyia Jamaludin |
|
|
Shore Capital (Joint Broker) |
+44 (0) 207 408 4090 |
|
Corporate Advisory David Coaten Harry Davies-Ball |
|
|
Corporate Broking Malachy McEntyre Isobel Jones |
|
|
|
|
|
J&E Davy (Joint Broker) |
+353 (0) 1 679 6363 |
|
Anthony Farrell |
|
|
Niall Gilchrist |
|
|
|
|
|
Optimum Strategic Communications |
+44 (0) 208 078 4357 |
|
Nick Bastin |
Poolbeg@optimumcomms.com |
|
Vici Rabbetts |
|
|
Elena Bates |
|
About Poolbeg Pharma plc
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets. For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.